BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 3, 2026
See today's BioWorld Asia
Home
» Lupin, Yoshindo spin out YL Biologics to develop biosimilars in Japan
To read the full story,
subscribe
or
sign in
.
Lupin, Yoshindo spin out YL Biologics to develop biosimilars in Japan
April 30, 2014
By
Cornelia Zou
HONG KONG – Indian pharmaceutical company Lupin Ltd. (BSE:500257, NSE:LUPIN) plans to launch a new company dedicated to biosimilars in Japan with its Japanese partner, Toyama-based pharmaceutical Yoshindo Inc.
BioWorld Asia
